About Transgene Biotek Limited.
Data last updated: 20 December 2025
Transgene Biotek Limited. is a public limited company based in Ida Bollaram, Telangana, India. It specialises in biotechnology, a part of the broader life sciences sector. Incorporated on 01 March 1990, the company has been in operation for over 36 years.
Registered with ROC Hyderabad under CIN L85195TG1990PLC011065. Listed on BSE: 526139.
Capital: an authorised share capital of ₹76 Cr and a paid-up capital of ₹75.77 Cr. It is led by directors including Kollipara Koteswara Rao and Swetha Marri.
Last AGM: 05 December 2024. Financial statements filed for year ended 31 March 2024. Office: Plot No:69 & 70 Ida Bollaram Sangareddy District., Telangana, India – 502325.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.04 Cr, a growth of 150% compared to the previous year.
Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Transgene Biotek. As per MCA filings, the company has open charges of ₹18.53 Cr and satisfied charges of ₹3.92 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website transgenebiotek.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressPlot No:69 & 70 Ida Bollaram Sangareddy District., Telangana, India – 502325
-
IndustryLife Sciences, Biotechnology
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Transgene Biotek Limited.
Transgene Biotek Limited. has one previous CIN (Corporate Identification Number): L85195AP1990PLC011065. The current CIN is L85195TG1990PLC011065, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L85195TG1990PLC011065 | Current |
| L85195AP1990PLC011065 | Previous |
Associated Brands with Transgene Biotek Limited.
Transgene Biotek Limited. operates one associated brand: Transgene Biotek. These brands represent Transgene Biotek Limited.'s diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Immunotherapies and drug delivery solutions for cancer are developed. | transgenebiotek.com |
Competitors & Alternatives of Transgene Biotek Limited.
Brands and companies operating in the same space as Transgene Biotek Limited. include Jazz Pharmaceuticals, Spark Therapeutics, BridgeBio and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Jazz Pharmaceuticals
|
Novel biopharmaceutical medicines are developed for unmet medical needs. | Dublin, Ireland, Ireland | 2003 |
Spark Therapeutics
|
Gene therapies for rare diseases including retinal dystrophies are developed. | Philadelphia, United States, United States | 2013 |
BridgeBio
|
Therapeutics for genetic diseases are developed through targeted interventions. | Palo Alto, United States, United States | 2015 |
Syndax
|
Targeted therapies for cancer treatment are developed. | Waltham, United States, United States | 2005 |
Insitro
|
An AI-enabled platform is developed for infectious disease treatment. | San Francisco, United States, United States | 2018 |
Alnylam
|
RNA interference-based therapeutics are developed for multiple disorders. | Cambridge, United States, United States | 2002 |
Revolution Medicines
|
Cancer therapies are developed using selective pathway inhibitors. | Redwood City, United States, United States | 2014 |
Blueprint Medicines
|
Selective kinase inhibitors are developed for genomically defined cancers. | Cambridge, United States, United States | 2008 |
ATAI
|
A biopharmaceutical company accelerating innovative mental health treatments. | Munich, Germany, Germany | 2018 |
Business Activity of Transgene Biotek Limited.
Transgene Biotek Limited. is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Transgene Biotek Limited.
Transgene Biotek Limited. is audited by VASAVI & CO (ICAI peer reviewed, certificate valid till 2026-11-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| VASAVI & CO (ICAI peer reviewed, certificate valid till 2026-11-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Transgene Biotek Limited.
Transgene Biotek Limited. is currently managed by 6 directors, with 11 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kollipara Koteswara Rao | Managing Director | 04 Mar 2020 | 6 Years 4 Months | Current |
|
Swetha Marri
Also directs:
Transgene Biotek Limited.
|
Director | 03 Jun 2020 | 6 Years 1 Months | Current |
|
Santhosh Kumar
Also directs:
Transgene Biotek Limited., Sanghi Spinners India Limited
|
Director | 12 Nov 2019 | 6 Years 7 Months | Current |
|
Sujana Kadiam
Also directs:
Transgene Biotek Limited.
|
Director | 17 Apr 2015 | 11 Years 2 Months | Current |
Financials of Transgene Biotek Limited. FY 2026 filings available
Transgene Biotek Limited. reported revenue of ₹21.12 Lakh (down 18.99% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Revenue from Operations | ₹21.12 Lakh | ₹26.07 Lakh | ₹23.29 Lakh | ₹8.67 Lakh |
| Other Income | ₹14.99 Lakh | ₹78.35 Lakh | ₹18.27 Lakh | ₹21.25 Lakh |
| Total Income | ₹36.11 Lakh | ₹1.04 Cr | ₹41.56 Lakh | ₹29.92 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹6,000 | ₹2.21 Lakh |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | -₹6.8 Lakh |
| Employee Benefit Expense | ₹14.73 Lakh | ₹30.78 Lakh | ₹31.12 Lakh | ₹28.79 Lakh |
| Finance Costs | ₹1.06 Cr | ₹24.3 Lakh | ₹12.91 Lakh | ₹22.68 Lakh |
| Depreciation & Amortisation | ₹19.91 Lakh | ₹9.32 Lakh | ₹9.23 Lakh | ₹9.92 Cr |
| Other Expenses | ₹60.74 Lakh | ₹1.08 Cr | ₹53.97 Lakh | ₹30.9 Lakh |
| Total Expenses | ₹2.01 Cr | ₹1.72 Cr | ₹1.07 Cr | ₹10.7 Cr |
| Profit Before Exceptional Items & Tax | -₹1.65 Cr | -₹67.6 Lakh | -₹65.73 Lakh | -₹10.4 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹1.65 Cr | -₹67.6 Lakh | -₹65.73 Lakh | -₹10.4 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹1.65 Cr | -₹67.6 Lakh | -₹65.73 Lakh | -₹10.4 Cr |
| attributable to Owners | ₹0 | - | - | ₹0 |
| attributable to NCI | ₹0 | - | - | ₹0 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹1.65 Cr | -₹67.6 Lakh | -₹65.73 Lakh | -₹10.4 Cr |
| EBITDA (computed) | -₹39.36 Lakh | -₹33.98 Lakh | -₹43.59 Lakh | -₹25.17 Lakh |
| Basic EPS | ₹-0.22 | ₹-0.09 | ₹0.09 | ₹-1.37 |
| Diluted EPS | ₹-0.22 | ₹-0.09 | ₹0.09 | ₹-1.37 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹143.66 Cr | ₹144.09 Cr | ₹142.33 Cr | ₹147.1 Cr |
| Non-current Assets | ₹142.63 Cr | ₹142.83 Cr | ₹141.22 Cr | ₹146.4 Cr |
| Current Assets | ₹1.03 Cr | ₹1.26 Cr | ₹1.11 Cr | ₹69.85 Lakh |
| Property, Plant & Equipment | ₹3.09 Cr | ₹3.29 Cr | ₹1.67 Cr | ₹1.85 Cr |
| Inventories | ₹3.4 Lakh | ₹3.4 Lakh | ₹3.39 Lakh | ₹9.46 Lakh |
| Trade Receivables | ₹84,000 | ₹84,000 | ₹83,000 | ₹84,400 |
| Cash & Equivalents | ₹6.07 Lakh | ₹28.43 Lakh | ₹76,000 | ₹1.51 Lakh |
| Equity (Net Worth) | ₹8.38 Cr | ₹10.03 Cr | ₹10.71 Cr | ₹17.38 Cr |
| Equity Share Capital | ₹75.77 Cr | ₹75.77 Cr | ₹75.77 Cr | ₹75.77 Cr |
| Borrowings (Non-current) | ₹6.8 Cr | ₹6.1 Cr | ₹5.08 Cr | ₹4.77 Cr |
| Borrowings (Current) | ₹10.34 Cr | ₹8.42 Cr | ₹8.92 Cr | ₹7.24 Cr |
| Total Debt (computed) | ₹17.14 Cr | ₹14.52 Cr | ₹14 Cr | ₹12.01 Cr |
| Current Liabilities | ₹13.26 Cr | ₹12.74 Cr | ₹11.14 Cr | ₹9.21 Cr |
| Total Liabilities | ₹135.28 Cr | ₹134.06 Cr | ₹131.62 Cr | ₹129.72 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Operating Cash Flow | -₹1.13 Lakh | ₹1.2 Cr | -₹57.41 Lakh | ₹8.61 Lakh |
| Investing Cash Flow | ₹15 Lakh | -₹1.7 Cr | -₹17.54 Lakh | -₹9.5 Lakh |
| Financing Cash Flow | -₹36.23 Lakh | ₹78.04 Lakh | ₹75.21 Lakh | ₹0 |
| Capital Expenditure | ₹0 | ₹0 | ₹0 | ₹0 |
| Free Cash Flow (computed) | -₹1.13 Lakh | ₹1.2 Cr | -₹57.41 Lakh | ₹8.61 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹22.36 Lakh | ₹27.67 Lakh | ₹26,000 | -₹89,500 |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹5.45 Lakh | ₹5.45 Lakh | ₹5.28 Lakh | ₹4.95 Lakh | ₹7.65 Lakh | ₹7.65 Lakh | ₹5.85 Lakh | ₹4.92 Lakh |
| Other Income | ₹14.99 Lakh | ₹0 | ₹0 | ₹0 | ₹4.38 Lakh | ₹4.48 Lakh | ₹4.38 Lakh | ₹65.19 Lakh |
| Total Income | ₹20.44 Lakh | ₹5.45 Lakh | ₹5.28 Lakh | ₹4.95 Lakh | ₹12.03 Lakh | ₹12.13 Lakh | ₹10.23 Lakh | ₹70.11 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹3.38 Lakh | ₹3.31 Lakh | ₹3.31 Lakh | ₹4.72 Lakh | ₹6.34 Lakh | ₹8.15 Lakh | ₹8.19 Lakh | ₹8.09 Lakh |
| Finance Costs | ₹27.68 Lakh | ₹27.35 Lakh | ₹26.43 Lakh | ₹24.55 Lakh | ₹19.12 Lakh | ₹1.73 Lakh | ₹1.73 Lakh | ₹1.73 Lakh |
| Depreciation & Amortisation | ₹4.98 Lakh | ₹4.98 Lakh | ₹4.98 Lakh | ₹4.98 Lakh | ₹2.35 Lakh | ₹2.32 Lakh | ₹2.32 Lakh | ₹2.32 Lakh |
| Other Expenses | ₹30.1 Lakh | ₹7.18 Lakh | ₹9.4 Lakh | ₹14.07 Lakh | ₹55.53 Lakh | ₹8.73 Lakh | ₹5.33 Lakh | ₹38.03 Lakh |
| Total Expenses | ₹66.14 Lakh | ₹42.82 Lakh | ₹44.12 Lakh | ₹48.32 Lakh | ₹83.34 Lakh | ₹20.93 Lakh | ₹17.57 Lakh | ₹50.17 Lakh |
| Profit Before Exceptional Items & Tax | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.8 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.8 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.8 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| attributable to Owners | ₹0 | ₹0 | - | - | - | - | - | ₹0 |
| attributable to NCI | ₹0 | ₹0 | - | - | - | - | - | ₹0 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.8 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| EBITDA (computed) | -₹13.04 Lakh | -₹5.04 Lakh | -₹7.43 Lakh | -₹13.84 Lakh | -₹49.84 Lakh | -₹4.75 Lakh | -₹3.29 Lakh | ₹23.99 Lakh |
| Basic EPS | ₹-0.06 | ₹-0.05 | ₹-0.05 | ₹-0.06 | ₹-0.09 | ₹-0.01 | ₹-0.01 | ₹0.03 |
| Diluted EPS | ₹-0.06 | ₹-0.05 | ₹-0.05 | ₹-0.06 | ₹-0.09 | ₹-0.01 | ₹-0.01 | ₹0.03 |
| Segment · Q2 FY25 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| NIL | ₹0 | ₹0 | ₹0 | ₹0 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Revenue from Operations | ₹21.12 Lakh | ₹26.07 Lakh | ₹23.9 Lakh | ₹8.67 Lakh |
| Other Income | ₹14.99 Lakh | ₹78.35 Lakh | ₹18.27 Lakh | ₹21.25 Lakh |
| Total Income | ₹36.11 Lakh | ₹1.04 Cr | ₹42.17 Lakh | ₹29.92 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹6,000 | ₹2.21 Lakh |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | -₹6.8 Lakh |
| Employee Benefit Expense | ₹14.73 Lakh | ₹30.78 Lakh | ₹31.12 Lakh | ₹28.79 Lakh |
| Finance Costs | ₹1.06 Cr | ₹24.3 Lakh | ₹12.91 Lakh | ₹22.68 Lakh |
| Depreciation & Amortisation | ₹19.91 Lakh | ₹9.32 Lakh | ₹9.23 Lakh | ₹9.92 Cr |
| Other Expenses | ₹60.74 Lakh | ₹1.08 Cr | ₹53.97 Lakh | ₹30.9 Lakh |
| Total Expenses | ₹2.01 Cr | ₹1.72 Cr | ₹1.07 Cr | ₹10.7 Cr |
| Profit Before Exceptional Items & Tax | -₹1.65 Cr | -₹67.6 Lakh | -₹65.12 Lakh | -₹10.4 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹1.65 Cr | -₹67.6 Lakh | -₹65.12 Lakh | -₹10.4 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹1.65 Cr | -₹67.6 Lakh | -₹65.12 Lakh | -₹10.4 Cr |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹1.65 Cr | -₹67.6 Lakh | -₹65.12 Lakh | -₹10.4 Cr |
| EBITDA (computed) | -₹39.36 Lakh | -₹33.98 Lakh | -₹42.98 Lakh | -₹25.17 Lakh |
| Basic EPS | ₹-0.22 | ₹-0.09 | ₹0.09 | ₹-1.37 |
| Diluted EPS | ₹-0.22 | ₹-0.09 | ₹0.09 | ₹-1.37 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹33.76 Cr | ₹34.18 Cr | ₹32.44 Cr | ₹37.22 Cr |
| Non-current Assets | ₹32.75 Cr | ₹32.95 Cr | ₹31.34 Cr | ₹36.53 Cr |
| Current Assets | ₹1.02 Cr | ₹1.24 Cr | ₹1.1 Cr | ₹69.01 Lakh |
| Property, Plant & Equipment | ₹3.09 Cr | ₹3.29 Cr | ₹1.67 Cr | ₹1.85 Cr |
| Inventories | ₹3.4 Lakh | ₹3.4 Lakh | ₹3.39 Lakh | ₹9.46 Lakh |
| Trade Receivables | ₹0 | ₹0 | ₹0 | ₹0 |
| Cash & Equivalents | ₹6.07 Lakh | ₹28.43 Lakh | ₹76,000 | ₹1.52 Lakh |
| Equity (Net Worth) | -₹9.2 Cr | -₹7.57 Cr | -₹6.87 Cr | -₹19.7 Lakh |
| Equity Share Capital | ₹75.77 Cr | ₹75.77 Cr | ₹75.77 Cr | ₹75.77 Cr |
| Borrowings (Non-current) | ₹6.8 Cr | ₹6.1 Cr | ₹5.08 Cr | ₹4.77 Cr |
| Borrowings (Current) | ₹10.34 Cr | ₹8.42 Cr | ₹8.92 Cr | ₹7.25 Cr |
| Total Debt (computed) | ₹17.14 Cr | ₹14.52 Cr | ₹14 Cr | ₹12.02 Cr |
| Current Liabilities | ₹13.14 Cr | ₹12.62 Cr | ₹11.04 Cr | ₹9.1 Cr |
| Total Liabilities | ₹42.96 Cr | ₹41.75 Cr | ₹39.31 Cr | ₹37.42 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|---|
| Operating Cash Flow | -₹1.13 Lakh | ₹1.2 Cr | -₹56.8 Lakh | ₹8.61 Lakh |
| Investing Cash Flow | ₹15 Lakh | -₹1.7 Cr | -₹17.54 Lakh | -₹9.5 Lakh |
| Financing Cash Flow | -₹36.23 Lakh | ₹78.04 Lakh | ₹75.21 Lakh | ₹0 |
| Capital Expenditure | ₹0 | ₹0 | ₹0 | ₹0 |
| Free Cash Flow (computed) | -₹1.13 Lakh | ₹1.2 Cr | -₹56.8 Lakh | ₹8.61 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹22.36 Lakh | ₹27.67 Lakh | ₹87,000 | -₹89,500 |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹5.45 Lakh | ₹5.45 Lakh | ₹5.28 Lakh | ₹4.95 Lakh | ₹7.65 Lakh | ₹7.65 Lakh | ₹5.85 Lakh | ₹4.92 Lakh |
| Other Income | ₹14.99 Lakh | ₹0 | ₹0 | ₹0 | ₹4.38 Lakh | ₹4.38 Lakh | ₹4.38 Lakh | ₹65.19 Lakh |
| Total Income | ₹20.44 Lakh | ₹5.45 Lakh | ₹5.28 Lakh | ₹4.95 Lakh | ₹12.03 Lakh | ₹12.03 Lakh | ₹10.23 Lakh | ₹70.11 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹3.38 Lakh | ₹3.31 Lakh | ₹3.31 Lakh | ₹4.72 Lakh | ₹6.34 Lakh | ₹8.15 Lakh | ₹8.19 Lakh | ₹8.09 Lakh |
| Finance Costs | ₹27.68 Lakh | ₹27.35 Lakh | ₹26.43 Lakh | ₹24.55 Lakh | ₹19.12 Lakh | ₹1.73 Lakh | ₹1.73 Lakh | ₹1.73 Lakh |
| Depreciation & Amortisation | ₹4.98 Lakh | ₹4.98 Lakh | ₹4.98 Lakh | ₹4.98 Lakh | ₹2.35 Lakh | ₹2.32 Lakh | ₹2.32 Lakh | ₹2.32 Lakh |
| Other Expenses | ₹30.1 Lakh | ₹7.18 Lakh | ₹9.4 Lakh | ₹14.07 Lakh | ₹55.53 Lakh | ₹8.73 Lakh | ₹5.33 Lakh | ₹38.03 Lakh |
| Total Expenses | ₹66.14 Lakh | ₹42.82 Lakh | ₹44.12 Lakh | ₹48.32 Lakh | ₹83.34 Lakh | ₹20.93 Lakh | ₹17.57 Lakh | ₹50.17 Lakh |
| Profit Before Exceptional Items & Tax | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.9 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.9 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.9 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹45.7 Lakh | -₹37.37 Lakh | -₹38.84 Lakh | -₹43.37 Lakh | -₹71.31 Lakh | -₹8.9 Lakh | -₹7.34 Lakh | ₹19.94 Lakh |
| EBITDA (computed) | -₹13.04 Lakh | -₹5.04 Lakh | -₹7.43 Lakh | -₹13.84 Lakh | -₹49.84 Lakh | -₹4.85 Lakh | -₹3.29 Lakh | ₹23.99 Lakh |
| Basic EPS | ₹-0.06 | ₹-0.05 | ₹-0.05 | ₹-0.06 | ₹-0.09 | ₹0.00 | ₹-0.01 | ₹0.03 |
| Diluted EPS | ₹-0.06 | ₹-0.05 | ₹-0.05 | ₹-0.06 | ₹-0.09 | ₹0.00 | ₹-0.01 | ₹0.03 |
| Segment · Q2 FY25 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| NIL | ₹0 | ₹0 | ₹0 | ₹0 |
Shareholding Pattern of Transgene Biotek Limited.
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 23.64%, retail and other public shareholders hold 76.36% of Transgene Biotek Limited.. The company had 13,767 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% | 23.64% |
| Public | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% | 76.36% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 23.64% | 23.64% | 23.64% |
| Public | 76.36% | 76.36% | 76.36% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | - |
Group Structure of Transgene Biotek Limited.
Transgene Biotek Limited. has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Transgene Biotek Limited.'s business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Peroral Bio Private Limited | U24230TG2020PTC147169 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Transgene Biotek Limited.
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Apr 2025 | Others | ₹1.5 Cr | Open |
| 30 Jan 2025 | Others | ₹6 Cr | Open |
| 08 Apr 2010 | Department of Biotechnology | ₹5.07 Cr | Open |
| 30 Jul 2008 | Ge Capital Services India | ₹8.63 Lakh | Open |
| 30 May 2005 | The Karur Vysya Bank Ltd. | ₹59.36 Lakh | Open |
Total charge records: 10 View all charges
Employees and EPFO Compliance at Transgene Biotek Limited.
View historical data on people associated with Transgene Biotek Limited., including employment history and EPFO contributions.
Employee Count & EPFO Data of Transgene Biotek Limited.
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Transgene Biotek Limited.
GSTIN & GST Filing Data of Transgene Biotek Limited.
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Transgene Biotek Limited.
Credit Ratings, Legal Cases & Regulatory Alerts of Transgene Biotek Limited.
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Transgene Biotek Limited.
MSME Payment Delays by Transgene Biotek Limited.
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Transgene Biotek Limited.
Subsidiaries & Group Companies of Transgene Biotek Limited.
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Transgene Biotek Limited. with ownership details.
MCA Filings & Documents of Transgene Biotek Limited.
MCA Filings & Documents of Transgene Biotek Limited.
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Transgene Biotek Limited.
Recent News on Transgene Biotek Limited.
Frequently Asked Questions about Transgene Biotek Limited.
Transgene Biotek Limited. is an active public limited company in the life sciences sector based in Ida Bollaram, Telangana, India. It was incorporated on 01 March 1990 (36+ years old) and is registered under CIN L85195TG1990PLC011065. Listed on BSE: 526139.
Transgene Biotek Limited. reported revenue of ₹1.04 Cr for FY 2025 (up 150.00% YoY).
The current directors of Transgene Biotek Limited. are:
- Kollipara Koteswara Rao
- Swetha Marri
- Ankita Jain
- Chowdari Prasad
- Santhosh Kumar
- Sujana Kadiam
The primary industry of Transgene Biotek Limited. is life sciences. The company specifically operates in biotechnology. The company is currently active in this sector.
Yes. Transgene Biotek Limited. is listed on BSE with code 526139.
Transgene Biotek Limited. can be reached at the registered office: Plot No:69 & 70 Ida Bollaram Sangareddy District, Telangana, India – 502325, or through the website transgenebiotek.com.